BioLife Solutions Inc

Recent decisive support failure on elevated volume and sliding below the 9EMA and 20EMA has shifted the medium-term bias bearish, despite the intact long-term uptrend. Short-term conditions remain unfavorable for buyers with no reversal patterns, so the preferred execution is to sell into any relief rallies around the broken support-turned-resistance near the 9/20 EMAs.

• ↑Q2 revenue $28.5 M (+21% YoY) with GAAP net income $45.1 M
• ↑Adjusted EBITDA $7.4 M (26% margin) and 64% GAAP gross margin
• ↓Key customers drive majority of sales, raising concentration risk